| 体内研究: |
In toxicology study in animals, Pidotimod (oral gavage; 800 mg/kg;12 months) is non-toxic in rats and is non-toxic dogs at 600 mg/kg. Pidotimod is non-teratogenic in rats (600 mg/kg orally or 1000 mg/kg IV) and has no effects on subsequent embryofoetal development in rats (up to 1000 mg/kg/day),it has no perinatal or postnatal toxic effects in rats (600 mg/kg orally). In ex vivo experiments in mice, Pidotimod (intraperitoneal administration; 200 mg/kg; 5 days) potentiats natural killer (NK) cell activity and produces an increase in the proliferative response to mitogens such as concanavalin A (ConA) and interleukin-2 (IL-2). Pidotimod (intraperitoneal administration; 10-100 mg/kg) normalizes depletion of peritoneal macrophage numbers, and significantly increases macrophage superoxide anion (O2–) production in methylprednisolone-induced immunosuppressed mice. |
| 参考文献: |
1. Ashok Mahashur, et al. Pidotimod: In-depth review of current evidence. Lung India 2. Ning Zhao, et al. Pidotimod: a review of its pharmacological features and clinical effectiveness in respiratory tract infections. Expert Rev Anti Infect Ther. 2019 Oct;17(10):803-818. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
4.094 ml |
20.469 ml |
40.938 ml |
| 5 mM |
0.819 ml |
4.094 ml |
8.188 ml |
| 10 mM |
0.409 ml |
2.047 ml |
4.094 ml |
| 50 mM |
0.082 ml |
0.409 ml |
0.819 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |